ResultsIQ

ResultsIQ › Latest results › Insecticides (India) Limited

Insecticides (India) Limited Q4 FY25 earnings call summary

NSE: INSECTICID · BSE: 532851

Earnings call of 28 May 2025, summarised by AI from the filing.

Insecticides India reported 32% revenue growth in Q4 FY25 and reiterates double-digit growth for FY26.

Key takeaways

  1. Change Inventory increased strategically for new season, expected to normalize by June-July.
  2. Driver Premiumization strategy and new product launches drive growth and margin expansion.
  3. Risk Manpower shortage after the war may impact production and placements in Q1.

Original filing on BSE

Insecticides (India) Limited Q1 FY27 results

As filed: Revenue ₹612 cr (−12% year on year), EBITDA ₹67.6 cr (−20% year on year), PAT ₹43.9 cr (−24% year on year), EBITDA margin 11.1% (−110 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹426 cr (+19% year on year), EBITDA ₹25.6 cr (−9% year on year), PAT ₹11.7 cr (−16% year on year), EBITDA margin 6.0% (−179 bps). Score 47 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 179 bps year on year. Other income 29% of PBT. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −13.9% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹385 cr (+8% year on year), EBITDA ₹27.4 cr (−12% year on year), PAT ₹10.5 cr (−38% year on year), EBITDA margin 7.1% (−154 bps). Score 33 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 154 bps year on year. Revenue fell 40% from last quarter. Share price after the results: −6.1% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹638 cr (+2% year on year), EBITDA ₹89.0 cr (0% year on year), PAT ₹59.0 cr (−3% year on year), EBITDA margin 14.0% (−24 bps). Score 32 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 24 bps year on year. Revenue fell 8% from last quarter. Share price after the results: +2.8% in 30 days (Nifty 500: +0.2%).
  • Q1 FY26: Revenue ₹691 cr (+5% year on year), EBITDA ₹84.0 cr (+18% year on year), PAT ₹58.0 cr (+18% year on year), EBITDA margin 12.2% (+135 bps). Score 40 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin rose 135 bps year on year. Profit rose ₹9.0 cr on a year ago, against ₹20.0 cr the year before. Share price after the results: −24.5% in 30 days (Nifty 500: +2.8%).
  • Q4 FY25: Revenue ₹359 cr (+32% year on year), EBITDA ₹28.0 cr (+211% year on year), PAT ₹14.0 cr (+75% year on year), EBITDA margin 7.8% (+450 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 450 bps year on year. Tax rate 36%. Profit fell 18% from last quarter. Share price after the results: +22.8% in 29 days (Nifty 500: +1.8%).
  • Q3 FY25: Revenue ₹358 cr (0% year on year), EBITDA ₹31.0 cr (+19% year on year), PAT ₹17.0 cr (+42% year on year), EBITDA margin 8.7% (+140 bps). Score 45 of 100, In line with trend. Revenue growth was in line with the company's own trend. EBITDA margin rose 140 bps year on year. Revenue fell 43% from last quarter.
  • Q2 FY25: Revenue ₹627 cr (−10% year on year), EBITDA ₹89.0 cr (+9% year on year), PAT ₹61.0 cr (+15% year on year), EBITDA margin 14.2% (+241 bps). Score 42 of 100, In line with trend. EBITDA margin rose 241 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 5% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Insecticides (India) Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.